Literature DB >> 24906060

An Evaluation of Statistical Methods for Analyzing Follow-Up Gaussian Laboratory Data with a Lower Quantification Limit.

John M Karon1, Ryan E Wiegand, Janneke H van de Wijgert, Peter H Kilmarx.   

Abstract

Laboratory data with a lower quantification limit (censored data) are sometimes analyzed by replacing non-quantifiable values with a single value equal to or less than the quantification limit, yielding possibly biased point estimates and variance estimates that are too small. Motivated by a three-period, three-treatment crossover study of a candidate vaginal microbicide in human immunodeficiency virus (HIV)-infected women, we consider four analysis methods for censored Gaussian data with a single follow-up measurement: nonparametric methods, mixed models, mixture models, and dichotomous measures of a treatment effect. We apply these methods to the crossover study data and use simulation to evaluate the statistical properties of these methods in analyzing the treatment effect in a two-treatment parallel-arm or crossover study with censored Gaussian data. Our simulated data and our mixed and mixture models consider treated follow-up data with the same variance as the baseline data or with an inflated variance. Mixed models have the correct type I error, the best power, the least biased Gaussian parameter treatment-effect estimates, and appropriate confidence interval coverage for these estimates. A crossover study analysis with a period effect can greatly increase the required study sample size. For both designs and both variance assumptions, published sample-size estimation methods do not yield a good estimate of the sample size to obtain the stated power.

Entities:  

Keywords:  Laboratory data; Mixed models; Mixture models; Quantification limit

Mesh:

Year:  2015        PMID: 24906060      PMCID: PMC6880227          DOI: 10.1080/10543406.2014.920858

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  19 in total

1.  Maximum likelihood inference for left-censored HIV RNA data.

Authors:  H S Lynn
Journal:  Stat Med       Date:  2001-01-15       Impact factor: 2.373

2.  Mixed effects models with censored data with application to HIV RNA levels.

Authors:  J P Hughes
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

3.  A simple analysis of a simple crossover trial with a dichotomous outcome measure.

Authors:  Hubert Schouten; Arnold Kester
Journal:  Stat Med       Date:  2010-01-30       Impact factor: 2.373

4.  The ghosts of departed quantities: approaches to dealing with observations below the limit of quantitation.

Authors:  Stephen Senn; Nick Holford; Hans Hockey
Journal:  Stat Med       Date:  2012-07-24       Impact factor: 2.373

5.  The use of mixture models for the analysis of survival data with long-term survivors.

Authors:  V T Farewell
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

6.  Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission.

Authors:  Jared M Baeten; Erin Kahle; Jairam R Lingappa; Robert W Coombs; Sinead Delany-Moretlwe; Edith Nakku-Joloba; Nelly R Mugo; Anna Wald; Lawrence Corey; Deborah Donnell; Mary S Campbell; James I Mullins; Connie Celum
Journal:  Sci Transl Med       Date:  2011-04-06       Impact factor: 17.956

7.  Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand.

Authors:  Eileen F Dunne; Sara Whitehead; Maya Sternberg; Sukhon Thepamnuay; Wanna Leelawiwat; Janet M McNicholl; Surin Sumanapun; Jordan W Tappero; Taweesap Siriprapasiri; Lauri Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2008-09-01       Impact factor: 3.731

8.  Comparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit.

Authors:  Ryan E Wiegand; Charles E Rose; John M Karon
Journal:  Stat Methods Med Res       Date:  2014-05-05       Impact factor: 3.021

9.  Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Authors:  Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetchotisakd; Jorge Corral; Neal David; Graeme Moyle; Marco Mancini; Lisa Percival; Rong Yang; Alexandra Thiry; Donnie McGrath
Journal:  Lancet       Date:  2008-08-23       Impact factor: 79.321

10.  Epidemiologic evaluation of measurement data in the presence of detection limits.

Authors:  Jay H Lubin; Joanne S Colt; David Camann; Scott Davis; James R Cerhan; Richard K Severson; Leslie Bernstein; Patricia Hartge
Journal:  Environ Health Perspect       Date:  2004-12       Impact factor: 9.031

View more
  1 in total

1.  Comparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit.

Authors:  Ryan E Wiegand; Charles E Rose; John M Karon
Journal:  Stat Methods Med Res       Date:  2014-05-05       Impact factor: 3.021

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.